These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29260607)

  • 41. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
    Pérez-Román DI; Ortiz-Haro AB; Ruiz-Medrano E; Contreras-Yáñez I; Pascual-Ramos V
    Rheumatol Int; 2018 Apr; 38(4):599-606. PubMed ID: 29264637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis.
    Kuwabara S; Tanimura S; Matsumoto S; Nakamura H; Horita T
    Ann Rheum Dis; 2020 Aug; 79(8):1125-1126. PubMed ID: 32213500
    [No Abstract]   [Full Text] [Related]  

  • 43. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173.
    Seo J; Kang JA; Suh DI; Park EB; Lee CR; Choi SA; Kim SY; Kim Y; Park SH; Ye M; Kwon SH; Park JD; Lim BC; Lee DH; Kang SJ; Choi M; Park SG; Chae JH
    J Allergy Clin Immunol; 2017 Apr; 139(4):1396-1399.e12. PubMed ID: 28041677
    [No Abstract]   [Full Text] [Related]  

  • 44. Successful treatment of rheumatoid neutrophilic panniculitis with tofacitinib.
    Almeida Junior HL; Furtado VD; Issaacson VS; Boff AL
    An Bras Dermatol; 2024; 99(4):644-647. PubMed ID: 38658238
    [No Abstract]   [Full Text] [Related]  

  • 45. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
    Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
    Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tofacitinib in ulcerative colitis.
    Archer TP; Moran GW; Ghosh S
    Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.
    Schulze-Koops H; Strand V; Nduaka C; DeMasi R; Wallenstein G; Kwok K; Wang L
    Rheumatology (Oxford); 2017 Jan; 56(1):46-57. PubMed ID: 28028154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
    Cohen S; Radominski SC; Gomez-Reino JJ; Wang L; Krishnaswami S; Wood SP; Soma K; Nduaka CI; Kwok K; Valdez H; Benda B; Riese R
    Arthritis Rheumatol; 2014 Nov; 66(11):2924-37. PubMed ID: 25047021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
    Charles-Schoeman C; Wicker P; Gonzalez-Gay MA; Boy M; Zuckerman A; Soma K; Geier J; Kwok K; Riese R
    Semin Arthritis Rheum; 2016 Dec; 46(3):261-271. PubMed ID: 27443588
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.
    McKesey J; Pandya AG
    J Am Acad Dermatol; 2019 Aug; 81(2):646-648. PubMed ID: 31009664
    [No Abstract]   [Full Text] [Related]  

  • 51. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D; O'Dell KM; Bandy JL; Boyce EG
    Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tofacitinib and other kinase inhibitors in the treatment of psoriasis.
    Ortiz-Ibáñez K; Alsina MM; Muñoz-Santos C
    Actas Dermosifiliogr; 2013 May; 104(4):304-10. PubMed ID: 23583515
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tofacitinib for the treatment of moderate-to-severe psoriasis.
    Chiricozzi A; Faleri S; Saraceno R; Bianchi L; Buonomo O; Chimenti S; Chimenti MS
    Expert Rev Clin Immunol; 2015 Apr; 11(4):443-55. PubMed ID: 25666451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation.
    Li Y; Huo J; Cao Y; Yu M; Zhang Y; Li Z; Li C; Zhang W
    Ann Rheum Dis; 2020 Sep; 79(9):1255-1257. PubMed ID: 32332076
    [No Abstract]   [Full Text] [Related]  

  • 55. Tofacitinib for the Treatment of Trachyonychia.
    Zhong X; Liu T; Wei L; Bai J; Fang H; Qiao J
    Am J Ther; 2024 Jul-Aug 01; 31(4):e468-e470. PubMed ID: 38976532
    [No Abstract]   [Full Text] [Related]  

  • 56. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.
    Craiglow BG; King BA
    J Invest Dermatol; 2014 Dec; 134(12):2988-2990. PubMed ID: 24940651
    [No Abstract]   [Full Text] [Related]  

  • 57. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C; Harness J; Tan H; Menter A
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
    Koga T; Sato T; Umeda M; Fukui S; Horai Y; Kawashiri SY; Iwamoto N; Ichinose K; Nakamura H; Kawakami A
    Clin Immunol; 2016 Dec; 173():147-148. PubMed ID: 27720846
    [No Abstract]   [Full Text] [Related]  

  • 60. JAK inhibitors: A broadening approach in rheumatoid arthritis.
    Lam S
    Drugs Today (Barc); 2016 Aug; 52(8):467-469. PubMed ID: 27722215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.